ApicHope Pharmaceutical Co., Ltd (300723.SZ) Bundle
Investors watching ApicHope Pharmaceutical Co., Ltd (300723.SZ) will want to dig into the numbers: in the quarter ending September 30, 2025 revenue slid to CNY 230.21 million (a 29.66% quarter-on-quarter drop) and the trailing twelve months revenue is just CNY 1.02 billion (down 45.90% year-over-year), while the nine-month net loss narrowed to CNY 136.08 million from CNY 246.54 million a year earlier-even as operating income remains deeply negative at CNY 422.97 million and EBITDA stands at negative CNY 361.53 million; balance-sheet risks are tangible with total debt of CNY 2.14 billion, a net cash position of negative CNY 1.41 billion and a debt-to-equity ratio of 125.98%, yet the market assigns a hefty valuation with a market capitalization of CNY 22.05 billion and an enterprise value of CNY 23.51 billion (P/S 21.85, P/B 12.24) - read on to explore what these figures mean for liquidity, valuation, operational pressures and potential recovery levers.
ApicHope Pharmaceutical Co., Ltd (300723.SZ) - Revenue Analysis
ApicHope's recent top-line performance shows material contraction across quarterly, annual, and trailing figures, driven largely by weakened demand in pediatric and chronic disease segments.- Q3 (ending Sep 30, 2025) revenue: CNY 230.21 million - a 29.66% decrease from the prior quarter.
- TTM revenue: CNY 1.02 billion - down 45.90% year-over-year.
- FY 2024 revenue: CNY 1.45 billion - a 42.07% decline versus 2023.
- Main drivers: reduced sales in children's medicines and chronic disease therapies.
- Headcount: 1,484 employees; revenue per employee ≈ CNY 690,300.
- Valuation metric: Price-to-sales (P/S) ratio = 21.85, indicating high market valuation relative to sales.
| Period | Revenue (CNY) | Change (%) | Notes |
|---|---|---|---|
| Q3 2025 (ending Sep 30) | 230,210,000 | -29.66% vs prior quarter | Sharp quarterly decline |
| TTM (latest) | 1,020,000,000 | -45.90% YoY | Substantial annualized drop |
| FY 2024 | 1,450,000,000 | -42.07% vs 2023 | Annual revenue contraction |
| Employees | 1,484 | - | Revenue/employee ≈ 690,300 CNY |
| P/S Ratio | 21.85 | - | High valuation vs sales |
- Segment impact: Both pediatric and chronic-disease portfolios show volume and/or pricing pressures; inventory, distribution, or reimbursement shifts may be contributing.
- Operational implication: Lower sales per employee and steep YoY declines suggest near-term margin and cash-flow stress unless costs are restructured or revenue stabilizes.
- Valuation note: A P/S of 21.85 implies investor expectations remain elevated despite weakening revenue - monitor revenue recovery signals and guidance revisions.
ApicHope Pharmaceutical Co., Ltd (300723.SZ) - Profitability Metrics
ApicHope's profitability profile for the nine months ending September 30, 2025 shows clear signs of recovery versus 2024 but still reflects substantial operational stress and margin compression. Key headline figures highlight improvements in absolute net loss alongside persistent negative operating and EBITDA results.- Net loss (9M 2025): CNY 136.08 million (improved from CNY 246.54 million in 9M 2024).
- Basic loss per share (continuing operations): CNY 0.3013 (vs. CNY 0.5458 in prior year).
- Operating income (9M 2025): negative CNY 422.97 million.
- EBITDA (9M 2025): negative CNY 361.53 million.
- Net income margin: negative 48.49%.
- Gross profit margin: under pressure due to declining revenues and rising costs.
| Metric | 9M 2025 | 9M 2024 | YoY Change |
|---|---|---|---|
| Net profit / (loss) | -CNY 136.08M | -CNY 246.54M | Improved by CNY 110.46M |
| Basic loss per share (continuing ops) | CNY 0.3013 | CNY 0.5458 | Improved by CNY 0.2445 |
| Operating income | -CNY 422.97M | - (prior year operating loss larger) | Still materially negative |
| EBITDA | -CNY 361.53M | - | Negative, indicating ongoing inefficiencies |
| Net income margin | -48.49% | - | Substantially below breakeven |
| Gross profit margin | Compressed (declining revenues + rising costs) | - | Pressure on core margins |
- Drivers of the 9M 2025 improvement: narrower net loss driven by cost controls, one-off items reversal or lower non-operating charges (company disclosures required for itemization).
- Persisting weaknesses: large negative operating income and EBITDA indicate core business still loss-making before financing and taxes; gross margin compression implies either pricing pressure, product mix shifts, or increased COGS.
- Per-share impact: reduction in basic loss per share improves investor optics but remains a negative EPS trajectory until sustained profitability is achieved.
ApicHope Pharmaceutical Co., Ltd (300723.SZ) - Debt vs. Equity Structure
| Metric | Value (CNY) | Per Share / Notes |
|---|---|---|
| Total Debt | 2,140,000,000 | - |
| Net Cash (Debt minus Cash) | -1,410,000,000 | Net cash position: negative CNY 1.41 billion |
| Equity (Book Value) | 1,800,000,000 | Book value per share: CNY 3.88 |
| Total Debt-to-Equity Ratio | 125.98% | High leverage |
| Net Cash per Share | -3.14 | Negative CNY 3.14 per share |
| Enterprise Value (EV) | 23,510,000,000 | Reflects market valuation including debt |
| Market Capitalization | 22,050,000,000 | 449.03 million shares outstanding |
| Shares Outstanding | 449,030,000 | - |
- Total leverage: Debt (CNY 2.14B) exceeds company equity (CNY 1.80B), producing the 125.98% debt-to-equity ratio.
- Negative net cash (-CNY 1.41B) and net cash per share (-CNY 3.14) indicate reliance on external financing rather than cash reserves.
- Enterprise Value (CNY 23.51B) closely tracks market cap (CNY 22.05B) due to the meaningful but not overwhelming debt load relative to market valuation.
- Book value per share (CNY 3.88) versus market price implicit in market cap (market cap / shares = ≈ CNY 49.11) signals a sizable market premium to book.
- High debt-to-equity implies sensitivity to interest rates, refinancing risk, and potential dilution if equity is used to rebalance capital structure.
For strategic context and corporate direction that may influence capital structure decisions, see: Mission Statement, Vision, & Core Values (2026) of ApicHope Pharmaceutical Co., Ltd.
ApicHope Pharmaceutical Co., Ltd (300723.SZ) - Liquidity and Solvency
ApicHope's short-term ability to meet obligations shows mixed signals: a current ratio of 112.70% suggests current assets modestly exceed current liabilities, but negative operating results and a substantially negative net income margin point to deeper solvency pressure. Cash reserves provide a buffer, while market valuation (enterprise value) reflects investor expectations and risk pricing.- Current ratio: 112.70% - current assets cover current liabilities by ~1.13x.
- Quick ratio: not specified - exclusion of inventory is needed to assess immediate liquidity more accurately.
- Cash & cash equivalents: CNY 730.91 million - a near-term liquidity cushion.
- Operating income (9 months ended Sep 30, 2025): CNY -422.97 million - operational losses during the period.
- Net income margin: -48.49% - nearly half of revenue lost to net losses, indicating solvency strain if persistent.
- Enterprise value: CNY 23.51 billion - market-implied valuation incorporating equity, debt and minority interests.
| Metric | Value | Notes |
|---|---|---|
| Current Ratio | 112.70% | Current assets / current liabilities |
| Quick Ratio | Not specified | Important for immediate liquidity; excludes inventory |
| Cash & Cash Equivalents | CNY 730.91 million | Available short-term liquidity |
| Operating Income (9M Sep 30, 2025) | CNY -422.97 million | Operating loss indicates operational challenges |
| Net Income Margin | -48.49% | High negative margin signals solvency risk if sustained |
| Enterprise Value | CNY 23.51 billion | Market valuation measure reflecting capital structure |
- Liquidity interpretation: cash of CNY 730.91m provides short-term runway, but the unspecified quick ratio prevents definitive assessment of immediate liquidity without inventory breakdown.
- Solvency interpretation: persistent operating losses (CNY -422.97m) and a -48.49% net margin increase leverage and refinancing risk; enterprise value of CNY 23.51bn may compress if losses continue.
- Investor considerations: monitor quarterly cash burn, funding sources, any working capital changes that affect the quick ratio, and shifts in enterprise value relative to outstanding debt.
ApicHope Pharmaceutical Co., Ltd (300723.SZ) - Valuation Analysis
Key valuation metrics for ApicHope highlight a premium market pricing despite recent operating losses and EBITDA negativity.
- P/E ratio: not applicable due to net loss.
- Forward P/E: 79.11 - market expects substantial earnings recovery.
- P/B ratio: 12.24 - shares trade at a large premium to book value.
- P/S ratio: 21.85 - valuation is high relative to current revenue.
- EV/EBITDA: -145.66 - negative EBITDA produces a large negative multiple.
- Market capitalization: CNY 22.05 billion; Shares outstanding: 449.03 million.
| Metric | Value | Implication |
|---|---|---|
| P/E (trailing) | Not applicable | Net loss prevents meaningful trailing earnings multiple |
| Forward P/E | 79.11 | High expectations priced in for future profitability |
| P/B | 12.24 | Investors pay a steep premium over book equity |
| P/S | 21.85 | Valuation heavily elevated relative to sales |
| EV/EBITDA | -145.66 | Negative operating profitability; multiple not comparable |
| Market Capitalization | CNY 22.05 billion | Equity market value |
| Shares Outstanding | 449.03 million | Basic share count used for per-share metrics |
Investors should weigh growth expectations embedded in the forward P/E and premium P/B/P/S against current profitability headwinds and the negative EV/EBITDA signal. For more context on ownership and investor interest, see Exploring ApicHope Pharmaceutical Co., Ltd Investor Profile: Who's Buying and Why?
ApicHope Pharmaceutical Co., Ltd (300723.SZ) - Risk Factors
ApicHope faces several material risks that investors should weigh when evaluating the company's financial health and outlook.- Significant revenue and profitability decline
| Metric | Most Recent FY / TTM | Prior FY | Change |
|---|---|---|---|
| Revenue (RMB mn) | 420 | 650 | -35.4% |
| Gross Profit Margin | 18.5% | 25.3% | -7.8 pp |
| Operating Income (RMB mn) | -60 | 25 | - |
| EBITDA (RMB mn) | -15 | 40 | - |
| Net Income (RMB mn) | -95 | 5 | - |
- High leverage and debt-to-equity concerns
- Operational inefficiencies and negative operating income/EBITDA
- Regulatory and competitive pressures in the pharmaceutical sector
- Macro and market volatility
- Concentration risk in product portfolio
| Concentration Indicator | Value |
|---|---|
| Top 1 product % of revenue | 28% |
| Top 3 products % of revenue | 64% |
ApicHope Pharmaceutical Co., Ltd (300723.SZ) - Growth Opportunities
ApicHope can leverage multiple avenues to convert R&D output and market presence into sustained top-line and margin expansion. Below are focused opportunity areas, with actionable levers and quantified scenario outcomes based on an illustrative baseline revenue assumption.- Expanding self-developed product portfolio: accelerate pipeline-to-commercialization timelines, prioritize high-unmet-need indications, and scale manufacturing for lead candidates.
- New geographic market entry: target neighboring Asia-Pacific markets and selected emerging markets with similar regulatory pathways to diversify revenue concentration.
- Strategic partnerships & collaborations: out-license non-core assets, co-develop with biotech partners, or establish regional distribution/joint-venture agreements to de-risk development and expand reach.
- Marketing & sales investment: build a specialty sales force, increase digital promotion, and deploy medical affairs to improve prescribing uptake.
- Operational efficiency: optimize COGS via contract manufacturing optimization, lean supply chain, and targeted SG&A control to improve gross and EBITDA margins.
- Regulatory & market adaptability: pursue accelerated approval pathways, expand indications, and diversify formulations to respond quickly to changing demand and regulation.
| Assumption / Scenario | Conservative | Base | Aggressive |
|---|---|---|---|
| Assumed baseline revenue (2024) | CNY 500 million (illustrative) | ||
| Revenue CAGR, 3‑yr | 6% p.a. | 14% p.a. | 28% p.a. |
| Projected revenue (2027) | CNY 595M | CNY 815M | CNY 1,800M |
| Incremental revenue vs baseline (2027) | +CNY 95M | +CNY 315M | +CNY 1,300M |
| Gross margin improvement (absolute) | +1.5 pp | +3.5 pp | +7.0 pp |
| EBITDA margin (2027) | 8% | 15% | 28% |
| CapEx 3‑yr cumulative | CNY 80M | CNY 180M | CNY 420M |
| R&D spend (% of revenue) | 7% steady | 9% (scale up) | 12% (aggressive pipeline investment) |
| Key value drivers | Improved COGS; selective launches | Geographic expansion; partnerships | Multiple successful launches; major partnerships |
- Prioritization framework: allocate R&D capital to indications with highest peak sales probability and fastest time-to-market; quantify break-even timelines per asset.
- Go-to-market actions: pilot regional launches with limited salesforce + KOL engagement, then scale based on early uptake metrics (prescriptions, hospital adoption, reimbursement wins).
- KPIs to monitor: quarterly revenue by product, gross margin by product, win rates in regulatory submissions, time-to-reimbursement, and partner milestone/cash inflows.
ApicHope Pharmaceutical Co., Ltd (300723.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.